Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4.

Alimentary pharmacology & therapeutics - 1 Sept 2008

Rossignol J F, Kabil S M, El-Gohary Y, Elfert A, Keeffe E B

Abstract excerpt

BACKGROUND: Nitazoxanide, licensed in the US for treatment of Cryptosporidium parvum and Giardia lamblia, inhibits hepatitis C virus replication in replicon systems. AIM: To evaluate the safety and efficacy of nitazoxanide monotherapy for the treatment of chronic hepatitis C. METHODS: This multic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Double-Blind Method
Share to Egypt

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Nitro Compounds

Share to RNA, Viral

Share to Thiazoles

Share to Treatment Outcome

Source

Identifiers

PMID: 18616643
DOI: 10.1111/j.1365-2036.2008.03781.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18616643-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4.PMID 18616643Read ↗

Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.Semantic proximity Read ↗

Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide.Semantic proximity Read ↗

[Chronic C hepatitis genotype 4].Semantic proximity Read ↗

A controlled study of nitazoxanide (NTZ) 3 years after treatment of hepatitis C genotype 4.Semantic proximity Read ↗

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.Semantic proximity Read ↗

Assessment of the activity of directly acting antivirals and other products against different genotypes of hepatitis C virus prevalent in resource-poor countries.Semantic proximity Read ↗

Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study.Semantic proximity Read ↗

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.Semantic proximity Read ↗

Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT.Semantic proximity Read ↗

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.Semantic proximity Read ↗

Daily interferon monotherapy for chronic hepatitis C in patients with normal or near-normal serum alanine transaminase levels: a comparison of two protocols.Semantic proximity Read ↗

Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.